Related Experiment Video

Updated: Aug 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma

Jared A Gollob1

  • 1Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. gollo001@mc.duke.edu

Clinical Genitourinary Cancer
|January 24, 2006
PubMed

Insights

Clear-cell renal cell carcinoma (RCC) treatment advances target key growth pathways. Multiple-kinase inhibitors like sorafenib show promise by blocking vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling in RCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Clear-cell renal cell carcinoma (RCC) involves loss of the von Hippel-Lindau protein, disrupting signaling pathways crucial for tumor growth.
  • Dysregulated pathways include VEGF/VEGFR, PDGF-beta/PDGFR-beta, and TGF-alpha/EGFR/Raf, promoting angiogenesis and tumor survival.

Purpose of the Study:

  • To review recent advances in clear-cell RCC biology and identify new therapeutic targets.
  • To present early clinical results of agents targeting these dysregulated pathways, focusing on multiple-kinase inhibitors (MKIs).

Main Methods:

  • Review of current literature on clear-cell RCC biology and targeted therapies.
  • Analysis of early clinical data for MKIs such as sorafenib, sunitinib, and AG013736.

Main Results:

  • MKIs targeting VEGFR and PDGFR-beta have shown significant advances in RCC treatment.
  • Sorafenib uniquely inhibits multiple Raf isoforms, impacting TGF-alpha/EGFR signaling and potentially enhancing VEGFR/PDGFR-beta inhibition.

Conclusions:

  • Understanding RCC biology has revealed new therapeutic targets.
  • Sorafenib and other MKIs represent promising treatments, with ongoing trials exploring combination therapies.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...